1 May 2010BiotechnologyCaroline Pallard

The risk of narrow protection

A peptide can be used, for example, as a vaccine, while an oligonucleotide can be used to silence a given gene whose expression product is involved in the development of a disease. Normally, biotechnology patent applications disclose a high number of peptides or oligonucleotides. The applicant usually follows this strategy in order to reduce the filing costs by gathering several peptides/oligonucleotides in a single application.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
8 April 2026   The acquisition of Munich-based biotech gives Gilead ownership of proprietary ADCs tech at a time when pharma and biotech companies are racing to secure next-generation cancer treatments.
Biotechnology
7 April 2026   On World Health Day 2026, despite data trending in the right direction, systemic barriers continue to limit female inventors—and women's health is suffering.
Biotechnology
27 March 2026   The Swiss pharma giant targets next-generation anti-IgE biologics as it looks to extend its dominance in the market.